On 2025-11-07 Reuters reported the European Commission is reconsidering delaying parts of the EU AI Act—implemented in August 2024—after lobbying from U.S. trade officials and major tech firms including Meta and Alphabet, with talks expected to culminate around 2025-11-19 and a final decision not before that date. The reconsideration centers on compliance burdens, trade friction with the U.S., and competitiveness. This matters because the AI Act is the world’s most comprehensive AI framework; delays could reshape global regulatory standards, affect market access and revenue for multinational tech companies, and complicate operational compliance and engineering roadmaps for firms building “high-risk” models. The Commission has not named which provisions may be paused; proposed delays may provoke civil society backlash and increased regulatory divergence between jurisdictions such as the U.S. and California (SB 53, signed 2025-09-29).

As of early November 2025, two developments pushed solid‐state batteries toward commercialization: NEO Battery Materials unveiled the P‐300 silicon anode—a metallurgical, micron‐scale silicon with polymer coatings aimed at improving interface stability and reducing fracturing for solid‐state systems in space and eVTOL applications—and ProLogium showcased its fourth‐generation all‐inorganic solid‐state lithium cell at IAA Mobility 2025 and outlined European mass‐production plans. ProLogium’s Taoyuan gigafactory has shipped over 500,000 cells, and it targets a Dunkirk, France plant producing 4 GWh by 2029 with full mass production by 2030. These moves matter because they address longevity and scaling barriers, accelerate adoption first in high‐value aerospace/eVTOL and then premium EVs, shift supply‐chain capacity to Europe, and bring regulatory and commercial incentives into play as the technology moves from R&D to scaled manufacture.

On November 5, 2025, following a Trump–Xi meeting at APEC in South Korea, China announced it will suspend a 24% retaliatory tariff on U.S. goods effective November 10, retaining a 10% "Liberation Day" levy and a 13% duty on soybeans; it will also remove export controls on 15 U.S. entities and suspend restrictions on 16 others for one year. The U.S. agreed to cut steep tariffs on Chinese imports from 145% to about 30% over three months, and U.S. officials said China committed to buying 12 million metric tons of soybeans by end‐2025 and 25 million annually through 2026–2028 (unverified by Beijing). Markets rallied on November 5. The truce should ease input costs, boost some export volumes and supply‐chain stability, but many measures are time‐bound and key issues remain unresolved, with enforcement and further negotiations to be watched into 2026.

In the second week of October 2025 the U.S. Department of Energy, under Secretary Chris Wright, canceled roughly $718 million in Manufacturing and Energy Supply Chains Office grants tied to advanced battery and clean-energy projects, affecting firms including Ascend Elements, American Battery Technology Co., Anovion, ICL Specialty Products and LuxWall; notable losses include ICL’s $197 million grant for a lithium‐iron‐phosphate cathode plant near St. Louis and Ascend’s Kentucky facility (a $316 million award, $206 million disbursed). DOE cited missed milestones, misalignment with current national priorities and lack of guaranteed taxpayer return, following intensified internal reviews (May 2025 memo). The pullbacks threaten startups’ scaling, supply‐chain stability for cathodes, synthetic graphite and recycling, and regional jobs in states like Kentucky and Missouri; the move forms part of broader cuts (~$7.6 billion) and signals a shift to selective, economics‐driven funding, prompting calls for clearer policy certainty and alternative financing.

On 2025-10-22 Google and IBM announced complementary quantum milestones that move the field toward practical use: Google’s 105-qubit Willow processor ran the new Quantum Echoes OTOC algorithm, producing verifiable expectation values (including NMR-inferred geometries for 15- and 28-atom molecules) and executing 13,000× faster than the best classical algorithm, while Willow reported single-qubit fidelity ~99.97%, entangling gates ~99.88% and readout ~99.5%; IBM demonstrated a quantum error‐correction routine running in real time on conventional AMD FPGAs at 10× the required speed, advancing its Starling roadmap toward 2029. These results matter because verifiability and faster, FPGA-enabled error correction make real applications (molecular modeling, materials, drug discovery) more plausible; next steps are scaling to logical qubits, external replication of Quantum Echoes and error‐correction results, and broader industry benchmarks, with Google projecting useful applications within five years.

The UN World Meteorological Organization confirms 2023–2025 will be the hottest three consecutive years in 176 years of records, following the hottest decade from 2015–2025 and new peaks in global greenhouse gases in 2024, making a temporary overshoot of the Paris 1.5 °C target near-certain; experts say staying below 1.5 °C without overshoot is now virtually impossible. With COP30 in Brazil in November 2025 approaching, only a minority of countries have submitted enhanced Nationally Determined Contributions while close to 100 countries—representing about two-thirds of global emissions—are preparing or updating NDCs. This escalation raises immediate risks to infrastructure, supply chains, real estate and financial liabilities and narrows the policy window: immediate priorities are finalizing more ambitious NDCs at COP30, scaling carbon removal and accelerating adaptation and resilience financing.

On October 29, 2025, the FDA and HHS released draft guidance proposing to accelerate biosimilar approvals by reducing human clinical trial requirements—including potentially waiving comparative efficacy trials—for biologic drugs made in living cells. The guidance aims to shorten development timelines and expand biosimilar availability, which could increase patient access, lower drug spending (notably for biologics targeted in Medicare’s Inflation Reduction Act negotiations), and prompt generics makers to invest while pressuring branded biologics’ revenue and sparking patent litigation and industry pushback. Risks include reduced human efficacy data and greater reliance on surrogate or non‐clinical metrics. The guidance is open for public comment; executives should watch stakeholder feedback, insurer and pharmacy benefit manager coverage shifts, legal and congressional responses, and accelerated launches of biosimilars such as potential denosumab competitors.

On Nov 5, 2025 Quantinuum commercially launched Helios, a 98 fully‐connected barium‐ion system claiming 99.9975% single‐qubit and 99.921% two‐qubit gate fidelity, offering 94 error‐detected logical qubits (50 used in magnetism simulations) and 48 fully error‐corrected logical qubits with 99.99% state preparation/measurement fidelity; Helios includes the Guppy Python language, NVIDIA GB200 via NVQLink, real‐time classical control, is available cloud and on‐premises, serves customers including Amgen, BMW, JPMorgan Chase, SoftBank and Sparrow, will be hosted in Singapore in 2026, and positions Quantinuum in DARPA’s QBI phase B toward a utility‐scale "Lumos" by 2033. A week later (Nov 12, 2025) IBM unveiled the experimental Loon chip—fabricated at Albany NanoTech—that adapts a cellphone‐signal algorithm for quantum error correction and, with Nighthawk due end‐2025, outlines a path to useful, error‐corrected machines by 2029 and some quantum‐advantage tasks by late 2026. These developments shift quantum computing toward enterprise utility and near‐term application testing.

On 6 November 2025 (UTC), UNESCO adopted global standards for neurotechnology comprising over 100 recommendations that introduce the term “neural data” and require protections to safeguard mental privacy, freedom of thought and to prevent intrusive uses such as “dream-time marketing.” The move responds to rapid advances in AI-driven neural interfaces and consumer devices that read brain activity or track eye movements and follows legislative activity such as the U.S. MIND Act and state neural-data privacy laws. The standards aim to set international norms across medical, commercial and civil-rights domains, elevating regulatory scrutiny of devices marketed for wellness or productivity; recommendations are nonbinding, so implementation depends on national and regional regulators. Expect governments, particularly in the U.S. and Europe, to refine laws and for companies to prepare for increased regulatory risk.

The Supreme Court’s West Virginia v. EPA (2022) ruling, highlighted in the past two weeks, drastically limits the EPA’s ability under Section 111(d) to force “generation‐shifting” from fossil fuels to renewables, holding such sweeping systemic changes require clear congressional authorization and reinforcing the major‐questions doctrine. The decision preserves EPA authority for plant‐level “fenceline” measures and leaves intact other tools—vehicle greenhouse gas rules, methane limits, air toxics, and broader air and water quality provisions—so agencies retain targeted regulatory options. Impact: major climate policy requiring economy‐wide generation shifts now needs legislation; courts will apply stricter review to agency actions; and the EPA is expected to pursue narrower, technology‐ or equipment‐based standards at individual facilities rather than systemwide mandates.